What question did this study set out to answer?

To provide updated recommendations from the Advisory Committee on Immunization Practices for the 2023–2024 formula COVID-19 vaccines targeting currently circulating SARS-CoV-2 variants.

October 10, 2023MMWR Morbidity and Mortality Weekly ReportOpen Access

Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023

View Full Paper

Ask AI

Bookmark

Authors

JRJoanna J. ReganCenters for Disease Control and Prevention DMDanielle MouliaCenters for Disease Control and Prevention RLRuth Link‐GellesIntermountain Healthcare

Discussion

Member takes

Implication

Clinical guidance reveals updated monovalent XBB.1.5 vaccination recommendations for individuals aged ≥6 months, indicating enhanced protection against emerging SARS-CoV-2 sublineages.

Key Points

To provide updated recommendations from the Advisory Committee on Immunization Practices for the 2023–2024 formula COVID-19 vaccines targeting currently circulating SARS-CoV-2 variants.
Review of regulatory decisions by the FDA regarding approvals and Emergency Use Authorizations of updated mRNA and protein subunit vaccines.
Assessment of waning immunity from prior bivalent vaccines against newly circulating SARS-CoV-2 XBB-sublineage variants.
The Advisory Committee on Immunization Practices recommended the updated 2023–2024 formula COVID-19 vaccines for all individuals aged ≥6 months.
The updated vaccines feature a monovalent XBB.1.5 component designed to broaden immunity and decrease severe COVID-19-associated outcomes, including hospitalization and death.

Cite This Study

Regan et al. (2023) studied this question.

synapsesocial.com/papers/69d968435e5bcb4e3b83638d https://doi.org/10.15585/mmwr.mm7242e1

View Full Paper

Ask AI

Bookmark

Implication

Clinical guidance reveals updated monovalent XBB.1.5 vaccination recommendations for individuals aged ≥6 months, indicating enhanced protection against emerging SARS-CoV-2 sublineages.

Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023

Discussion

Member takes

Implication

Key Points

Cite This Study

Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider